Similar articles

• Neurodevelopmental outcome at 36 months' corrected age of preterm infants in the Multicenter Indomethacin Intraventricular Hemorrhage Prevention Trial.

  Ment LR, Vohr B, Oh W, Scott DT, Allan WC, Westerveld M, Duncan CC, Ehrenkranz RA, Katz KH, Schneider KC, Makuch RW. Ment LR, et al. Pediatrics. 1996 Oct;98(4 Pt 1):714-8. Pediatrics. 1996. PMID: 8885951 Clinical Trial.
• Cognitive outcome at 4 1/2 years of very low birth weight infants enrolled in the multicenter indomethacin intraventricular hemorrhage prevention trial.

  Ment LR, Westerveld M, Makuch R, Vohr B, Allan WC. Ment LR, et al. Pediatrics. 1998 Jul;102(1 Pt 1):159-60. doi: 10.1542/peds.102.1.159. Pediatrics. 1998. PMID: 9714645 Clinical Trial. No abstract available.
• Risk period for intraventricular hemorrhage of the preterm neonate is independent of gestational age.

  Ment LR, Oh W, Ehrenkranz RA, Philip AG, Schneider K, Katz KH, Taylor KJ, Duncan CC, Makuch RW. Ment LR, et al. Semin Perinatol. 1993 Oct;17(5):338-41. Semin Perinatol. 1993. PMID: 8290976 Clinical Trial. No abstract available.
• Indomethacin for prevention of neonatal intraventricular hemorrhage.

  Lamp KC, Reynolds MS. Lamp KC, et al. DICP. 1991 Dec;25(12):1344-8. doi: 10.1177/106002809102501213. DICP. 1991. PMID: 1815433 Review.
• Prevention of neonatal intraventricular hemorrhage.

  Perlman JM, Volpe JJ. Perlman JM, et al. Clin Neuropharmacol. 1987 Apr;10(2):126-42. doi: 10.1097/00002826-198704000-00003. Clin Neuropharmacol. 1987. PMID: 3332606 Review. No abstract available.